In the analysis, there was as much as a 92 percent difference in median overall survival (OS) seen between patients treated in randomized controlled trials and "real world" data.
Sandra Hanner
Advertisement
Articles by Sandra Hanner
An analysis of the phase 3 NAPOLI-1 trial supports the benefits of adding MM-398 chemotherapy for the treatment of patients with metastatic pancreatic cancer who were previously treated with Gemzar.
Among patients with metastatic gastric cancer treated with the PD-1 inhibitor Keytruda, the agent showed promising activity, according to updated findings from the KEYNOTE-012 study presented at the Gastrointestinal Cancers Symposium.
Advertisement
Latest Updated Articles
Updated Study Results Shows Activity for Keytruda in Gastric CancerPublished: January 16th 2015 | Updated:
Analysis of NAPOLI-1 Study Shows MM-398 Benefit in Metastatic Pancreatic CancerPublished: January 20th 2015 | Updated:
Pancreatic Cancer Survival Rates Lower in Real World Versus Clinical TrialsPublished: April 13th 2016 | Updated:
Advertisement
Advertisement
Trending on CURE
1
With Cancer, 'Your Outlook Will be Significant in Beating this Disease'
2
FDA Grants Exousia Pro Orphan Drug Designation in Glioma
3
Sharing Insights Into a Multiple Myeloma Journey
4
What to Know About the FDA Approval of Blenrep for Multiple Myeloma
5
